Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0GY4H
|
||||
| Former ID |
DNCL001718
|
||||
| Drug Name |
Taberminogene vadenovec
|
||||
| Synonyms |
Trinam (TN)
|
||||
| Indication | Vascular restinosis following vascular graft surgery [ICD10:T82.858A] | Phase 3 | [1] | ||
| Company |
Ark Therapeutics
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 3 | Target Info | Modulator | [2] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| NetPath Pathway | TNFalpha Signaling Pathway | ||||
| Pathway Interaction Database | VEGF and VEGFR signaling network | ||||
| VEGFR3 signaling in lymphatic endothelium | |||||
| Reactome | VEGF binds to VEGFR leading to receptor dimerization | ||||
| WikiPathways | Signaling by VEGF | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00895479) Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence. U.S. National Institutes of Health. | ||||
| REF 2 | Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.